



ASX release

29 February 2016

## **CPT-1 Reimbursement Update**

### ***Private health plans to reimburse SphygmoCor test***

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which noninvasively measures the central arterial pressure waveform, central aortic blood pressures and arterial stiffness indices, today announced that one large national health plan and three regional health plans have initiated reimbursement of the SphygmoCor test. The four health plans cover over 18 million lives.

AtCor Medical CEO, Duncan Ross, said: "We are pleased that these private health plans have initiated reimbursement so soon after the US CPT-1 code was introduced. This enables millions of patients to benefit from noninvasive central arterial pressure waveform analysis, and supports our commercial launch to doctors following the availability of the Category 1 CPT code.

"We are continuing to work with a leading private reimbursement consultant to educate private payers, and discussions continue with a number of other private plans. AtCor has also confirmed reimbursement to doctors in several Medicare regions and under a number of state Medicaid plans."

Medicare is the national government health program for retirees, people with disabilities, and people with end-stage renal disease which covers 55 million lives. It is estimated that 40 percent of Medicare patients are afflicted with hypertension. Medicaid is the state-based health coverage program for low income patients, and covers 71 million lives.

AtCor is initially targeting four major metropolitan areas through its specialist sales force supported by a telemarketing campaign. The company is also hiring additional sales staff in regions with a high concentration of reimbursed lives. The rollout is proceeding as planned.

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 8815 8811  
[p.manley@atcormedical.com](mailto:p.manley@atcormedical.com)

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m.0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)